Ginkgo Bioworks Holdings Profit Margin 2020-2022 | DNA

Current and historical gross margin, operating margin and net profit margin for Ginkgo Bioworks Holdings (DNA) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Ginkgo Bioworks Holdings net profit margin as of March 31, 2022 is 0%.
Ginkgo Bioworks Holdings Annual Profit Margins
Ginkgo Bioworks Holdings Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $4.957B $0.314B
Ginkgo Bioworks platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo Bioworks, formerly known as Soaring Eagle Acquisition Corp., is based in NEW YORK.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $170.283B 10.36
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.670B 16.84
Biohaven Pharmaceutical Holding (BHVN) United States $10.157B 0.00
Arcus Biosciences (RCUS) United States $1.815B 46.02
Emergent Biosolutions (EBS) United States $1.640B 7.02
Myovant Sciences (MYOV) United Kingdom $1.243B 0.00
Zymeworks (ZYME) Canada $0.354B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.098B 0.00
Ambrx Biopharma (AMAM) United States $0.098B 0.00
SQZ Biotechnologies (SQZ) United States $0.095B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00